Arbutus Biopharma Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
22.97
Mar 3 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Jul 8, 2016
Tekmira Pharmaceuticals Corp Annual Shareholders Meeting (Estimated) - 5:00PM EDT - Add to calendar
May 19, 2016
Arbutus Biopharma Corp Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
May 10, 2016
Arbutus Biopharma Corp at Bank of America Merrill Lynch Health Care Conference Add to calendar
May 4, 2016
Q1 2016 Arbutus Biopharma Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 17, 2016
Arbutus Biopharma Corp at Barclays Global Healthcare Conference
Mar 15, 2016
Arbutus Biopharma Corp at ROTH Conference
Mar 9, 2016
Q4 2015 Arbutus Biopharma Corp Earnings Release
Mar 7, 2016
Arbutus Biopharma Corp at Cowen Health Care Conference
Feb 23, 2016
Arbutus Biopharma Corp at RBC Capital Markets Healthcare Conference
Feb 11, 2016
Arbutus Biopharma Corp at Leerink Partners Global Healthcare Conference
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Pky
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.